⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

July 2, 2024Open Access

Supplementary Figure 3 from Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes

David König Michael T. Sandholzer Sarp Uzun Andreas Zingg Reto Ritschard Helen Thut Katharina Glatz Elisabeth A. Kappos Dirk J. Schaefer Christoph Kettelhack Jakob Passweg Andreas Holbro Katharina Baur Michael Medinger Andreas Buser Didier Lardinois Lukas T. Jeker Nina Khanna Frank Stenner Benjamin Kasenda Krisztián Homicskó Matthias S. Matter Natália Rodrigues Mantuano Alfred Zippelius Heinz Läubli

View Full Paper

Ask AI

Bookmark

Share

Abstract

Supplementary Figure 3. Regressing soft tissue metastasis (Biopsy 10 weeks after TIL transfer). No vital tumor is detectable.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

König et al. (2024) studied this question.

synapsesocial.com/papers/68e61b74b6db6435875ae053 https://doi.org/10.1158/2326-6066.26144570

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure 2 from Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes2024
2Supplementary Figure 2 from Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes2024
3Supplementary Figure 4 from Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes2024
4Supplementary Figure 4 from Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes2024
5Supplementary Figure 7 from Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes2024